Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “GANYMED PHARMACEUTICALS AG [DE]”

9 pharma patents match "GANYMED PHARMACEUTICALS AG [DE]" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 9
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 9 pharmaceutical patents matching "GANYMED PHARMACEUTICALS AG [DE]" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

9 results for “GANYMED PHARMACEUTICALS AG [DE]” · 30,257 patents in full index Clear search

  1. US 2018326059

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS AG [DE] · Granted Nov 15, 2018 · Expires Nov 10, 2038

    granted
  2. US 2018000900

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS AG [DE] · Granted Jan 4, 2018 · Expires Dec 30, 2037

    granted
  3. US 2016185873

    MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS AG [DE] · Granted Jun 30, 2016 · Expires Jun 25, 2036

    granted
  4. US 2016159901

    DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS

    GANYMED PHARMACEUTICALS AG [DE] · Granted Jun 9, 2016 · Expires Jun 4, 2036

    granted
  5. EP 2976360

    THERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    GANYMED PHARMACEUTICALS AG [DE] · Granted Jan 27, 2016 · Expires Jan 22, 2036

    granted
  6. EP 2958945

    KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    GANYMED PHARMACEUTICALS AG [DE] · Granted Dec 30, 2015 · Expires Dec 25, 2035

    granted
  7. EP 2852409

    KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    GANYMED PHARMACEUTICALS AG [DE] · Granted Apr 1, 2015 · Expires Mar 27, 2035

    granted
  8. EP 2847225

    ANTIKÖRPER GEGEN CLAUDIN 18.2 FÜR DIE KREBSDIAGNOSE

    GANYMED PHARMACEUTICALS AG [DE] · Granted Mar 18, 2015 · Expires Mar 13, 2035

    granted
  9. EP 2591003

    KREBSTHERAPIE MITTELS CLDN6-ZIELGERICHTETER ANTIKÖRPER IN VIVO

    GANYMED PHARMACEUTICALS AG [DE] · Granted May 15, 2013 · Expires May 10, 2033

    granted